Researchers believe that macrophage cells in the liver that harbor such inert HIV are not a part of the viral reservoir.

As a result, cure treatments may have to approach these two targets differently.

The latest collection of articles stems from a tiny study in Uganda, neither peer-reviewed nor presented at a conference.

Post-HIV-treatment viral control is more likely in those treated very early.

A new study analyzes nuances in a cohort of six people who also received stem cell transplants for blood cancers.

An antibody treatment plus an immune-stimulating agent delayed viral rebound in primates infected with HIV-like virus.

Scientists have discovered a swifter and more precise way to edit the genome of immune cells, opening doors for cancer and HIV therapies.

Researchers drew immune cells from people on effective HIV treatment, cultured the cells and reinfused 40 million of them.

Such latently infected cells remain under the radar of antiretroviral treatment, which only works on replicating cells.

Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.